These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29453099)

  • 1. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies.
    Lindh M; Rydell GE; Larsson SB
    Curr Opin Virol; 2018 Jun; 30():24-31. PubMed ID: 29453099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
    Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
    Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Virus Cure: Targets and Future Therapies.
    Lee HW; Lee JS; Ahn SH
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
    Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
    Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.
    Lu F; Wang J; Chen X; Xu D; Xia N
    Front Med; 2017 Dec; 11(4):502-508. PubMed ID: 29170915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
    Baugh SDP
    Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.